DK1501848T3 - Syntese af låst nukleinsyrederivater - Google Patents

Syntese af låst nukleinsyrederivater

Info

Publication number
DK1501848T3
DK1501848T3 DK03718663T DK03718663T DK1501848T3 DK 1501848 T3 DK1501848 T3 DK 1501848T3 DK 03718663 T DK03718663 T DK 03718663T DK 03718663 T DK03718663 T DK 03718663T DK 1501848 T3 DK1501848 T3 DK 1501848T3
Authority
DK
Denmark
Prior art keywords
lna
synthesis
nucleic acid
acid derivatives
locked nucleic
Prior art date
Application number
DK03718663T
Other languages
Danish (da)
English (en)
Inventor
Mads Detlef Sorensen
Jesper Wengel
Troels Koch
Signe M Christensen
Christoph Rosenbohm
Daniel Sejer Darwin C Pedersen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of DK1501848T3 publication Critical patent/DK1501848T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK03718663T 2002-05-08 2003-05-08 Syntese af låst nukleinsyrederivater DK1501848T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200712 2002-05-08
DKPA200201214 2002-08-16
PCT/DK2003/000305 WO2003095467A1 (en) 2002-05-08 2003-05-08 Synthesis of locked nucleic acid derivatives

Publications (1)

Publication Number Publication Date
DK1501848T3 true DK1501848T3 (da) 2007-10-22

Family

ID=29421786

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03718663T DK1501848T3 (da) 2002-05-08 2003-05-08 Syntese af låst nukleinsyrederivater

Country Status (9)

Country Link
EP (1) EP1501848B1 (enExample)
JP (1) JP4476802B2 (enExample)
AT (1) ATE369375T1 (enExample)
AU (1) AU2003222743B2 (enExample)
CA (1) CA2484526C (enExample)
DE (1) DE60315444T2 (enExample)
DK (1) DK1501848T3 (enExample)
ES (1) ES2290448T3 (enExample)
WO (1) WO2003095467A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
HUE037352T2 (hu) 2002-04-05 2018-08-28 Roche Innovation Ct Copenhagen As A HIF-1alfa expresszálódását módosító oligomer vegyületek
CA2506576C (en) 2002-11-18 2018-03-06 Santaris Pharma A/S Antisense gapmer oligonucleotides
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
EP1606406B2 (en) 2003-03-21 2013-11-27 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
EP1706489B9 (en) 2003-12-23 2011-01-05 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
NZ555644A (en) 2004-11-09 2009-04-30 Santaris Pharma As Potent LNA oligonucleotides for the inhibition of HIF-1A expression
US20060154888A1 (en) 2004-11-09 2006-07-13 Santaris Pharma A/S LNA oligonucleotides and the treatment of cancer
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
DK2002004T3 (en) 2006-03-23 2015-11-30 Roche Innovation Ct Copenhagen As LITTLE INTERNAL SEGMENTED INTERFERENCE RNA
PL2666859T3 (pl) 2006-04-03 2019-09-30 Roche Innovation Center Copenhagen A/S Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA
CA3024953A1 (en) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
WO2008006369A1 (en) * 2006-07-14 2008-01-17 Santaris Pharma A/S Adenosine receptor antagonists
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
WO2008113830A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
EP2173373B1 (en) 2007-06-06 2020-04-15 Sarepta Therapeutics, Inc. Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
DK2195428T3 (en) 2007-09-19 2014-03-03 Applied Biosystems Llc SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF
KR101889518B1 (ko) 2007-10-04 2018-08-17 로슈 이노베이션 센터 코펜하겐 에이/에스 마이크로ＭＩＲｓ
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2315832B1 (en) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna mediated modulation of colony stimulating factors
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
EP2591106A1 (en) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
JP6262131B2 (ja) * 2011-07-21 2018-01-17 ローディア オペレーションズ グアーヒドロキシプロピルトリメチルアンモニウムクロリドおよびヘアトリートメント組成物でのその使用
WO2013095132A1 (en) 2011-12-22 2013-06-27 Interna Technologies B.V. Mirna for treating head and neck cancer
EP2794627B1 (en) 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
EP2943570B1 (en) 2013-01-14 2018-01-03 Pierfrancesco Tassone Inhibitors of mirnas 221 and 222 for anti-tumor activity in multiple myeloma
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
SG10201908122XA (en) 2013-06-27 2019-10-30 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
EP3201339A4 (en) 2014-10-03 2018-09-19 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
US10731154B2 (en) 2015-02-15 2020-08-04 Arcturus Therapeutics, Inc. Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides
TW201718618A (zh) 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
KR102422625B1 (ko) 2015-10-09 2022-07-20 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
KR102604132B1 (ko) 2015-12-14 2023-11-17 콜드스프링하버러보러토리 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머
SG11201809002RA (en) 2016-04-29 2018-11-29 Univ Nanyang Tech G-quadruplex-containing antisense oligonucleotides
EP3494219A1 (en) 2016-08-03 2019-06-12 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
SG11202001590RA (en) 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
CN111566212A (zh) 2017-11-03 2020-08-21 因特尔纳技术有限公司 miRNA分子，等同物，安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
JP2021513508A (ja) 2018-02-12 2021-05-27 インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． 抗がんマイクロｒｎａ及びその脂質製剤
EP3788169A4 (en) 2018-05-04 2022-08-10 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
MX2022014151A (es) 2020-05-11 2022-11-30 Stoke Therapeutics Inc Oligomeros antisentido de opa1 para tratamiento de afecciones y enfermedades.
JP2024506371A (ja) 2021-02-12 2024-02-13 メランド ファーマシューティカルズ，インコーポレイテッド 低酸素症及び虚血関連障害を処置する薬剤、組成物及び方法
EP4313074A1 (en) 2021-03-26 2024-02-07 Neumirna Therapeutics ApS Microrna-27b inhibitors
EP4313073A1 (en) 2021-03-26 2024-02-07 Neumirna Therapeutics ApS Microrna-134 inhibitors
AU2022287241A1 (en) 2021-06-04 2023-12-14 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
JP2024531363A (ja) 2021-08-17 2024-08-29 コリア アドバンスト インスティテュート オブ サイエンス アンド テクノロジー Ｃａｖ３．１遺伝子を標的とするアンチセンスオリゴヌクレオチド及びその使用
JP2024531342A (ja) 2021-08-19 2024-08-29 ニューミルナ セラピューティクス エーピーエス アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
EP4332239A1 (en) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis
EP4450626A1 (en) 2023-04-21 2024-10-23 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Fnip2 inhibitors for treating ataxia telangiectasia
KR20250050953A (ko) * 2023-07-21 2025-04-15 레드필드 파마슈티컬 인크. 탄소 고리형 뉴클레오시드, 올리고뉴클레오티드 및 이의 제조 방법과 의약 용도
EP4512899A1 (en) 2023-08-23 2025-02-26 Lipigon Pharmaceuticals AB Angptl4 aso compositions for treatment of atherosclerosis in humans

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180924A (zh) * 1999-05-04 2011-09-14 桑塔里斯制药公司 L-核糖-lna类似物
JP4413493B2 (ja) * 2000-10-04 2010-02-10 サンタリス ファーマ アー／エス プリンｌｎａ類似体の改善された合成方法

Also Published As

Publication number Publication date
ATE369375T1 (de) 2007-08-15
ES2290448T3 (es) 2008-02-16
JP2005532319A (ja) 2005-10-27
EP1501848B1 (en) 2007-08-08
DE60315444T2 (de) 2008-04-30
AU2003222743B2 (en) 2008-12-11
WO2003095467A1 (en) 2003-11-20
JP4476802B2 (ja) 2010-06-09
AU2003222743A1 (en) 2003-11-11
DE60315444D1 (en) 2007-09-20
CA2484526A1 (en) 2003-11-20
EP1501848A1 (en) 2005-02-02
CA2484526C (en) 2009-10-13

Similar Documents

Publication Publication Date Title
DK1501848T3 (da) Syntese af låst nukleinsyrederivater
WO2007031548A3 (en) Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof
WO2007136817A3 (en) Substituted aryl piperidinylalkynyladenosines as a2ar agonists
UA95600C2 (en) Synthesis scheme for lacosamide
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
WO2007085895A3 (en) Fap inhibitors
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
MY161575A (en) Mixture for the treatment of urea-containing fertilizers
WO2009137455A3 (en) Cure accelerators for anaerobic curable compositions
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
MY150490A (en) Improved process for producing hydrocyanic acid
GEP20125512B (en) Process for synthesis of agomelatin
WO2005005389A3 (en) Malonamide derivatives
GB0521508D0 (en) Organic compounds
IL208290A0 (en) Process for the preparation of 10-deacetyl-bis-7, 10- trichloroacetylbaccatin iii
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
WO2004002990A3 (en) Synthesis of purine derivatives
IL172015A0 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
WO2011038152A3 (en) Toll-like receptor modulators and uses thereof
WO2007066158A3 (en) HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
WO2007049295A3 (en) An improved one pot process for making key intermediate for gemcitabine hcl
WO2011161255A3 (en) Processes for the resolution of nitrogen substituted (s) - 5 -alkoxy- 2 -aminotetralin derivatives
WO2006043175A3 (en) Process for preparing purine compounds
WO2005054175A3 (en) New process for the preparation of nitrooxyderivatives of paracetamol
BRPI0519785A2 (pt) processo para a preparação de isocianatos de tiofenossulfonila